GlassScriptPhysician profile
Raj M Eliazer
NPI 1144210238
$14,096.79
in general payments reported to CMS, 2019-2025
58 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,319 · 2020: $2,415 · 2021: $2,580 · 2022: $3,608 · 2023: $2,960 · 2024: $76.47 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,175.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,064.69 | 2021-2025 | |
| Ucb, INC. | $988.39 | 2019-2023 | Nayzilam, Briviact |
| Teva Pharmaceuticals USA, INC. | $984.41 | 2019-2023 | Ajovy, Austedo Xr, Austedo |
| Biogen, INC. | $716.50 | 2019-2023 | Vumerity, Tysabri |
| Amgen INC. | $672.62 | 2019-2023 | Aimovig |
| Sunovion Pharmaceuticals INC. | $589.20 | 2019-2022 | |
| Genzyme Corporation | $496.07 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $490.32 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $478.77 | 2019-2021 | |
| Sk Life Science, INC. | $473.32 | 2020-2023 | |
| Allergan, INC. | $469.40 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $453.36 | 2022 | |
| Lundbeck LLC | $442.83 | 2020-2023 | Vyepti |
| Avanir Pharmaceuticals, INC. | $367.98 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $327.15 | 2022-2024 | Ingrezza, Ongentys |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raj Eliazer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.